December 2022 Review

While major ASX and US indices ended 2022 in the red, HB Biotechnology fared much better, delivering a 6.8% return for the calendar year, following a staggering 51.8% return in the second half of the year.  In the following review, our Managing Director, Charlie Williams, reviews investment performance in 2022 and how we’re positioning for 2023.